Francois Brisebois
Stock Analyst at Oppenheimer
(1.74)
# 3,284
Out of 5,067 analysts
88
Total ratings
38.64%
Success rate
-2.5%
Average return
Main Sectors:
Stocks Rated by Francois Brisebois
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AQST Aquestive Therapeutics | Maintains: Outperform | $7 → $8 | $5.78 | +38.41% | 3 | Sep 8, 2025 | |
| SVRA Savara | Maintains: Outperform | $5 → $6 | $5.21 | +15.16% | 6 | Aug 15, 2025 | |
| SNSE Sensei Biotherapeutics | Maintains: Outperform | $70 → $80 | $8.98 | +791.00% | 2 | Mar 28, 2025 | |
| ABEO Abeona Therapeutics | Initiates: Outperform | $16 | $4.59 | +248.58% | 1 | Mar 5, 2025 | |
| OVID Ovid Therapeutics | Upgrades: Outperform | $4 | $1.49 | +168.46% | 1 | Jan 29, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Outperform | $65 → $72 | $82.11 | -12.31% | 7 | Jan 22, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $59 → $61 | $35.27 | +72.95% | 6 | Jan 13, 2025 | |
| MNMD Mind Medicine (MindMed) | Reiterates: Outperform | $20 | $11.75 | +70.21% | 4 | Dec 17, 2024 | |
| TRDA Entrada Therapeutics | Maintains: Outperform | $25 → $28 | $9.89 | +183.11% | 2 | Nov 6, 2024 | |
| AVDL Avadel Pharmaceuticals | Maintains: Outperform | $29 → $30 | $22.92 | +30.89% | 8 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $143 → $163 | $190.86 | -14.59% | 4 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $55 | $21.67 | +153.81% | 5 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $0.62 | +2,331.12% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 | $8.00 | -25.00% | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $3.97 | +177.08% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $29.37 | -52.33% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $4.12 | +506.80% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $65 | $17.17 | +278.68% | 5 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $5.23 | +91.20% | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $152 | $5.89 | +2,480.65% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $36 | $18.12 | +98.68% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $60 | $0.26 | +22,748.44% | 3 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7,200 → $5,400 | $1.68 | +321,328.57% | 2 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $11 | $3.38 | +225.44% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $18 | $3.57 | +404.63% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $5.18 | +865.25% | 1 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,240 | $0.85 | +381,480.50% | 1 | Feb 4, 2020 |
Aquestive Therapeutics
Sep 8, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $5.78
Upside: +38.41%
Savara
Aug 15, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $5.21
Upside: +15.16%
Sensei Biotherapeutics
Mar 28, 2025
Maintains: Outperform
Price Target: $70 → $80
Current: $8.98
Upside: +791.00%
Abeona Therapeutics
Mar 5, 2025
Initiates: Outperform
Price Target: $16
Current: $4.59
Upside: +248.58%
Ovid Therapeutics
Jan 29, 2025
Upgrades: Outperform
Price Target: $4
Current: $1.49
Upside: +168.46%
Tarsus Pharmaceuticals
Jan 22, 2025
Maintains: Outperform
Price Target: $65 → $72
Current: $82.11
Upside: -12.31%
Harmony Biosciences Holdings
Jan 13, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $35.27
Upside: +72.95%
Mind Medicine (MindMed)
Dec 17, 2024
Reiterates: Outperform
Price Target: $20
Current: $11.75
Upside: +70.21%
Entrada Therapeutics
Nov 6, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $9.89
Upside: +183.11%
Avadel Pharmaceuticals
Oct 31, 2024
Maintains: Outperform
Price Target: $29 → $30
Current: $22.92
Upside: +30.89%
Oct 31, 2024
Maintains: Outperform
Price Target: $143 → $163
Current: $190.86
Upside: -14.59%
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $21.67
Upside: +153.81%
Aug 19, 2024
Reiterates: Outperform
Price Target: $15
Current: $0.62
Upside: +2,331.12%
Aug 16, 2024
Reiterates: Outperform
Price Target: $6
Current: $8.00
Upside: -25.00%
Aug 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $3.97
Upside: +177.08%
Aug 14, 2024
Reiterates: Outperform
Price Target: $14
Current: $29.37
Upside: -52.33%
Jun 25, 2024
Initiates: Outperform
Price Target: $25
Current: $4.12
Upside: +506.80%
Jun 13, 2024
Maintains: Outperform
Price Target: $55 → $65
Current: $17.17
Upside: +278.68%
May 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $5.23
Upside: +91.20%
Aug 30, 2023
Reiterates: Outperform
Price Target: $152
Current: $5.89
Upside: +2,480.65%
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $18.12
Upside: +98.68%
Apr 3, 2023
Maintains: Outperform
Price Target: $100 → $60
Current: $0.26
Upside: +22,748.44%
Feb 6, 2023
Maintains: Outperform
Price Target: $7,200 → $5,400
Current: $1.68
Upside: +321,328.57%
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $3.38
Upside: +225.44%
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $3.57
Upside: +404.63%
Oct 29, 2021
Initiates: Outperform
Price Target: $50
Current: $5.18
Upside: +865.25%
Feb 4, 2020
Initiates: Buy
Price Target: $3,240
Current: $0.85
Upside: +381,480.50%